Health Care & Life Sciences » Biotechnology | Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc. | Ownership

Companies that own Protagonist Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
3,180,583
14.99%
15,017
0%
06/30/2018
BVF Partners LP
2,617,967
12.34%
1,200,000
1.7%
08/10/2018
Farallon Capital Management LLC
2,289,884
10.79%
1,379,655
0.14%
08/07/2018
Great Point Partners LLC
1,473,609
6.95%
1,473,609
1.95%
06/30/2018
The Vanguard Group, Inc.
514,208
2.42%
5,060
0%
06/30/2018
Adage Capital Management LP
500,000
2.36%
-500,000
0.01%
06/30/2018
Renaissance Technologies LLC
478,300
2.25%
426,100
0.01%
06/30/2018
Cormorant Asset Management LP
382,139
1.8%
0
0.26%
06/30/2018
DWS Investment GmbH
294,190
1.39%
284,917
0%
06/30/2018
BlackRock Fund Advisors
251,592
1.19%
-387,097
0%
06/30/2018

About Protagonist Therapeutics

View Profile
Address
7707 Gateway Boulevard
Newark California 94560
United States
Employees -
Website http://www.protagonist-inc.com
Updated 07/08/2019
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It offers proprietary peptide technology platform, which discovers and develops new chemical entities to address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.